
    
      This study consists of a 1 week screening period, a 54 week treatment period, and a 12 week
      follow-up period, requiring a total of 7 trial site visits: Visit 1(screening visit, Week
      -1), Visit 2 (enrollment visit, Day 0), Visit 3 (Week 2), Visit 4 (Week 6), Visit 5 (Week 30)
      and Visit 6 (Week 54) and Visit 7 (follow-up visit, Week 66).
    
  